RayKnowChina Research Map
Shortlist

Langfang

Hebei Yanda Lu Daopei Hospital

河北燕达陆道培医院

Listed for 4 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Hebei Yanda Lu Daopei Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Multiple myeloma多发性骨髓瘤1 paper led
  2. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病7 papers led
  3. Aplastic anaemia再生障碍性贫血2 papers led
  4. Fanconi anaemia范可尼贫血1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 1 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.06%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Langfang for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesCAR-T & cell therapyRelapse & resistance
Papers it led1
  1. Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma.2025Blood advancesFree full text
All its trials on ClinicalTrials.gov, any status3
  1. A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MMStatus unknownNCT04412889Lead sponsorEarly phase 1Start 2020-06
  2. A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT03751293Lead sponsorPhase 1Start 2019-01
  3. CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid MalignanciesStatus unknownNCT03312205Study sitePhase 1/Phase 2Start 2017-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 7 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 3.1%.

Papers led
7
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 2220242025: 112025

1 hospital in Langfang for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
    Phase
    N/A
    Started
    2026-11
    Registry
    NCT07919470

    Age 14 years to 65 years (registered criteria)

    Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing, Langfang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsCAR-T & cell therapyStem cell transplant
Departments in papersPathology / laboratory medicine
Papers it led7
  1. First report of B-lymphoblastic leukemia harboring LRRFIP1::FGFR1 fusion: expanding the clinical spectrum of myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.2025Annals of hematologyFree full text
  2. The second adult case of NUTM1 fusion-positive B-cell lymphoblastic leukemia: A recurring pattern of poor prognosis.2024Annals of hematology
  3. Successful treatment of the first adult case of ZMIZ1::ABL1-positive B cell lymphoblastic leukemia with dasatinib, chimeric antigen receptor T-cell therapy, and allogeneic hematopoietic stem cell transplantation.2024Cancer genetics
  4. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.2023Frontiers in immunologyFree full text
  5. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.2022Cancer immunology, immunotherapy : CIIFree full text
  6. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemi2022Genes, chromosomes & cancer
  7. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic L2021Frontiers in immunologyFree full text
All its trials on ClinicalTrials.gov, any status14
  1. CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL)TerminatedNCT04508842Lead sponsorPhase 1Start 2020-10
  2. A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLStatus unknownNCT04129099Lead sponsorEarly phase 1Start 2019-10
  3. A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLStatus unknownNCT03825731Lead sponsorEarly phase 1Start 2019-01
  4. A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLCompletedNCT03825718Lead sponsorEarly phase 1Start 2019-01
  5. Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCTNot yet recruitingNCT07919470Study siteN/AStart 2026-11
  6. Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic LeukemiaCompletedNCT05563545Study sitePhase 1Start 2022-07
  7. Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic LeukemiaStatus unknownNCT05225831Study siteEarly phase 1Start 2021-08
  8. Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte LeukemiaStatus unknownNCT04546893Study siteN/AStart 2020-09
  9. Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04546906Study siteN/AStart 2020-09
  10. Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaStatus unknownNCT04792593Study siteN/AStart 2020-12
  11. Senl_1904A and Senl_1904B Chimeric Antigen Receptor (CAR) T-Cell in the Treatment of r/ r Acute B Lymphocytic LeukemiaStatus unknownNCT03840317Study sitePhase 1Start 2019-01
  12. CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.Status unknownNCT03671460Study sitePhase 1Start 2018-09
  13. CD19-CAR-T Cells in Patients With R/R B-ALLStatus unknownNCT03574168Study sitePhase 1Start 2018-07
  14. Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)CompletedNCT03173417Study sitePhase 1/Phase 2Start 2017-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

1 hospital in Langfang for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantChildren
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Langfang for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

河北燕达陆道培医院

Hebei Yanda Lu Daopei Hospital

廊坊

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Hebei Yanda Lu Daope Hospital; Hebei Yanda Ludaopei Hospital; Hebei Yanda Lu Daopei Hospital & Beijing Ludaopei Hospital; Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital; Yanda Lu Daopei Hospital; Hebei Yanda Medical Research Institute; Hebei Yanda Hospital; Hebei Yanda Ludaopei Hospital Co., Ltd.

Suggest a correctionDownload the data